Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q01469

UPID:
FABP5_HUMAN

ALTERNATIVE NAMES:
Epidermal-type fatty acid-binding protein; Fatty acid-binding protein, epidermal; Psoriasis-associated fatty acid-binding protein homolog

ALTERNATIVE UPACC:
Q01469; B2R4K0

BACKGROUND:
The Fatty acid-binding protein 5, known alternatively as Epidermal-type fatty acid-binding protein, is integral to the cytosolic transport of fatty acids and endocannabinoids. It selectively delivers fatty acids to the nucleus, activating peroxisome proliferator-activated receptor delta, thereby promoting cell proliferation and survival. Additionally, FABP5 plays a role in synaptic carrier functions at central synapses, controlling retrograde endocannabinoid signaling and influencing inflammation and keratinocyte differentiation.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Fatty acid-binding protein 5 offers a promising avenue for developing novel therapeutic interventions, especially in managing inflammation, enhancing skin health, and regulating metabolic processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.